# Floatz vs Insight Floatz records 253 monthly visits with -36.8% month-over-month growth and Contact for Pricing pricing. Insight records 2,761 monthly visits with -2.7% growth and Free pricing. | Metric | [Floatz](https://openaitools.app/tool/floatz-ai) | [Insight](https://openaitools.app/tool/insight) | | :--- | :--- | :--- | | Website URL | https://floatz.ai | https://insightai.dev | | Categories | AI Healthcare, AI Research Tool, AI For Data Analytics, AI Report Generator | AI Research Tool, AI Healthcare, AI Assistant, AI Article Summarizer | | Pricing Model | Contact for Pricing | Free | | Monthly Visits | 253 | 2,761 | | MoM Growth Rate | -36.8% | -2.7% | | Primary Market | Switzerland | United States | | Direct Visits | 94 | 1,088 | | Review Score | 3.8 | 4.4 | | Saved Count | 17 | 2 | | Supported Platforms | Website | Website | ## Floatz Floatz positions itself as an AI research engine for life-science questions. Rather than relying on manual literature reviews, it indexes and summarises scientific publications so users can interrogate a therapeutic area, a target or a company's science and get a consolidated view in minutes rather than weeks. The platform is aimed at two overlapping audiences: investors doing scientific due diligence on biotech and life-science assets, and research teams who need fast, cited groundwork on drug targets, pathways and emerging evidence. Results are presented as structured summaries with the underlying papers kept as traceable references. Floatz does not publish self-serve pricing; the site directs buyers to request access, which is typical of enterprise/investor-grade research tools where seats and data volumes are negotiated. Because capabilities and data coverage evolve quickly, it is worth confirming the current scope of literature coverage directly with the vendor. **Pricing & Plans:** Contact for pricing — Floatz does not list public plans on its website and directs interested users to get in touch. - **Scientific literature search and analysis:** Search and analyse large bodies of scientific papers to answer specific research or therapeutic-area questions. - **Structured summaries with sources:** Distils dense literature into readable, source-linked summaries so findings can be traced back to the original publications. - **Target and pathway discovery support:** Helps surface high-potential drug targets and relevant biological pathways across large document sets. - **Due-diligence workflows for investors:** Frames evidence around scientific risk so life-science investors can review a thesis before capital is committed. - **Built for non-programmers:** A web interface aimed at analysts and researchers rather than bioinformaticians, so no coding or command-line work is required. **Strengths:** Focuses on life-science evidence rather than generic text, so outputs are framed around targets, pathways and scientific risk; Saves the weeks normally spent on manual literature triage; Aims to keep summaries traceable to source publications, which matters for audit and investment memos; Browser-based, so analysts and investors can use it without a bioinformatics stack **Limitations:** No public pricing or self-serve trial published on the site, so onboarding likely requires a sales conversation; Coverage and accuracy depend on the literature and data sources it indexes, which are not fully documented publicly; Best suited to life-science questions — it is not a general-purpose research assistant [Profile (Markdown)](https://openaitools.app/tool/floatz-ai.md) ## Insight Insight was created to remove one of the least rewarding parts of research: reading. Its PubMed feature searches across tens of millions of peer-reviewed biomedical articles, using language models to produce a one-click scientific summary instead of a list of citations to chase. Researchers can point it at a question and get a structured starting point within seconds. Beyond summarization, the platform covers hypothesis generation and experimental design, exporting designs as a PDF report. It also integrates specialized data: MyVariant brings in hundreds of millions of human variants, MyGene covers millions of genes across tens of thousands of species, and NIH RePORTER and ClinicalTrials.gov supply insight into funded projects and ongoing or completed trials. A separate high-throughput discovery module aims at target, biomarker, and prognostic marker identification. Insight is positioned as a free tool, with an optional donation channel to support the team. Its outputs are grounded in peer-reviewed sources, but the platform is a research accelerator rather than a clinical decision tool, so conclusions should still be validated by domain experts. **Pricing & Plans:** Insight is free to use. The site asks visitors to try the tool and offers an optional donation link to support the mission; a waitlist exists for the high-throughput discovery module. - **One-click scientific summaries:** Searches over 36 million peer-reviewed biomedical articles across roughly 30,000 journals and condenses findings into readable summaries. - **Hypothesis generation:** Turns a research question into candidate hypotheses to explore, saving the blank-page phase of a study. - **Experimental design export:** Drafts experimental designs that can be exported as a PDF report for review or planning. - **Gene and variant data:** Integrates MyGene and MyVariant for gene and mutation lookups across millions of genes and human variants. - **Grants and trials:** Connects NIH RePORTER and ClinicalTrials.gov so users can see funded projects and ongoing or completed clinical trials. **Strengths:** Free to use with no cost barrier; Grounded in peer-reviewed and official biomedical data sources; Covers the full path from literature to hypothesis to design; Integrated gene, variant, trial, and grant data in one place **Limitations:** AI-generated summaries still need expert verification before use; Some advanced discovery features are waitlisted; Interface is utilitarian and aimed at researchers rather than casual users [Profile (Markdown)](https://openaitools.app/tool/insight.md) ## Frequently Asked Questions ### How do Floatz and Insight compare in monthly traffic? Floatz has 253 monthly visits, while Insight has 2,761. Traffic estimates describe audience size, not product quality. ### How do their growth rates compare? Floatz has a month-over-month growth rate of -36.8%; Insight has -2.7%. ### How does pricing compare? Floatz: Contact for Pricing. Contact for pricing — Floatz does not list public plans on its website and directs interested users to get in touch. Insight: Free. Insight is free to use. The site asks visitors to try the tool and offers an optional donation link to support the mission; a waitlist exists for the high-throughput discovery module. ## Alternatives | # | Tool Name | Monthly Visits | MoM Growth Rate | Pricing Model | Summary | Profile (Markdown) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | 1 | [Semantic Scholar](https://openaitools.app/tool/semantic-scholar) | 8,198,672 | +5.8% | Free | A free, AI-powered academic search engine for 240M+ papers across every scientific field | [.md](https://openaitools.app/tool/semantic-scholar.md) | | 2 | [Consensus](https://openaitools.app/tool/consensus) | 6,014,388 | -1.2% | Freemium | AI academic search engine for peer-reviewed science | [.md](https://openaitools.app/tool/consensus.md) | | 3 | [SciSpace](https://openaitools.app/tool/scispace) | 4,464,111 | +8.6% | Freemium | AI research platform for reading, understanding and writing scientific papers | [.md](https://openaitools.app/tool/scispace.md) | | 4 | [Elicit](https://openaitools.app/tool/elicit) | 1,751,507 | +3.1% | Freemium | AI research assistant for evidence-based literature review and synthesis | [.md](https://openaitools.app/tool/elicit.md) | | 5 | [Rayyan](https://openaitools.app/tool/rayyan) | 1,116,437 | +7.9% | Freemium | AI-assisted systematic review software for screening, extraction, and evidence synthesis at scale | [.md](https://openaitools.app/tool/rayyan.md) | | 6 | [Scite](https://openaitools.app/tool/scite) | 841,974 | +1.1% | Free Trial, Contact for Pricing | AI answers grounded in 300M+ scholarly full texts | [.md](https://openaitools.app/tool/scite.md) | | 7 | [Connected Papers](https://openaitools.app/tool/connected-papers) | 750,576 | +3.1% | Freemium | Explore the academic literature as a visual graph of related papers | [.md](https://openaitools.app/tool/connected-papers.md) | | 8 | [Dr.Oracle](https://openaitools.app/tool/dr-oracle) | 723,847 | -1.2% | Free Trial | Guideline-directed medical answers with citations, built for clinicians | [.md](https://openaitools.app/tool/dr-oracle.md) | | 9 | [Paperguide](https://openaitools.app/tool/paperguide) | 371,972 | -2.9% | Freemium | AI-native workspace for literature reviews and auditable systematic reviews | [.md](https://openaitools.app/tool/paperguide.md) | | 10 | [Paper Digest](https://openaitools.app/tool/paper-digest) | 97,202 | -7.1% | Freemium | AI-powered platform to read, write, and stay current with research | [.md](https://openaitools.app/tool/paper-digest.md) | --- Source: https://openaitools.app/compare/floatz-ai-vs-insight More Markdown: [Categories](https://openaitools.app/categories.md) · [Traffic rankings](https://openaitools.app/rankings.md) · [llms.txt](https://openaitools.app/llms.txt)